2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
88
Lymphoma, Follicular
50
Lymphoma, Non-Hodgkin
36
Lymphoma, Large B-Cell, Diffuse
29
Lymphoma
29
Lymphoma, Mantle-Cell
26
Lymphoma, B-Cell, Marginal Zone
22
Lymphoma, B-Cell
18
Recurrence
13
Neoplasms
11
Leukemia
7
Leukemia, B-Cell
6
Burkitt Lymphoma
5
Leukemia, Hairy Cell
4
Waldenstrom Macroglobulinemia
3
Neoplasm, Residual
3
Melanoma
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumors
2
Disease
2
Dendritic Cell Sarcoma, Interdigitating
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Bronchiolitis Obliterans Syndrome
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Tumor Lysis Syndrome
1
Solid Cancers
1
Interventions
ofatumumab
1
ocrelizumab
1
obinutuzumab
1
ibritumomab tiuxetan
1
Rituximab
1
Paclitaxel
1
Diphenhydramine
1
Cetirizine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Oncology Patients Receiving Chemotherapy
×
obinutuzumab
×
Clear all
NCT04189588
2023-10-06
versus
TerSera Therapeutics LLC
Phase 2
Completed
34 enrolled
11 charts